FTSE

FTSE 100 plunges as Burnham triggers bond markets turmoil

FTSE 100 plunges as Burnham triggers bond markets turmoil

FTSE 100 Poised to Extend Decline as Equity Sentiment Sours

FTSE 100 Set to Fall and Miss Out on Tech Rally

FTSE 100 Poised for Rebound, Pound Climbs

FTSE 100’s likely new entrant puts a British spin on the AI boom

Hardware reseller’s trick will be to convince investors artificial intelligence can augment its services rather than replace them

BP removes chair Albert Manifold over ‘serious’ governance and conduct concerns

BP has removed its chair, Albert Manifold, following serious concerns raised by the board regarding governance, oversight, and conduct. The FTSE 100 company announced his immediate departure on Tuesday, noting that he had served in the role for only eight months.

GSK to buy US cancer treatment firm Nuvalent for $10.6bn

British drugmaker’s new chief executive Luke Miels announces one of its biggest dealsBusiness live – latest updatesGSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications. The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based biotech that develops cancer drugs, including three for lung cancer. GSK will pay $124 a share...

Tate & Lyle agrees £2.7bn takeover by US rival in new blow to London market

Venerable but struggling UK firm backs deal with Chicago-based Ingredion putting nearly 500 jobs worldwide at riskTate & Lyle has agreed to a £2.7bn takeover by its US rival Ingredion, in a deal that could put hundreds of jobs at risk and represents yet another loss for London’s struggling stock market. The FTSE 250 business, which makes artificial sweeteners such as Splenda, has agreed to a deal that values it at 615p per share, about 60% above its price before news of a possible...

Tate & Lyle agrees £2.7bn takeover by US rival in new blow to London market

Venerable but struggling UK firm backs deal with Chicago-based Ingredion putting nearly 500 jobs worldwide at riskTate & Lyle has agreed to a £2.7bn takeover by its US rival Ingredion, in a deal that could put hundreds of jobs at risk and represents yet another loss for London’s struggling stock market. The FTSE 250 business, which makes artificial sweeteners such as Splenda, has agreed to a deal that values it at 615p per share, about 60% above its price before news of a possible...

Tate & Lyle agrees £2.7bn takeover by US rival in new blow to London market

Venerable but struggling UK firm backs deal with Chicago-based Ingredion putting nearly 500 jobs worldwide at riskTate & Lyle has agreed to a £2.7bn takeover by its US rival Ingredion, in a deal that could put hundreds of jobs at risk and represents yet another loss for London’s struggling stock market. The FTSE 250 business, which makes artificial sweeteners such as Splenda, has agreed to a deal that values it at 615p per share, about 60% above its price before news of a possible...